Aspira Womens Health (FRA:CUL) Additional Paid-In Capital : €479.83 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Additional Paid-In Capital?

Aspira Womens Health's quarterly additional paid-in capital declined from Sep. 2023 (€482.13 Mil) to Dec. 2023 (€473.11 Mil) but then increased from Dec. 2023 (€473.11 Mil) to Mar. 2024 (€479.83 Mil).

Aspira Womens Health's annual additional paid-in capital increased from Dec. 2021 (€444.18 Mil) to Dec. 2022 (€480.10 Mil) but then declined from Dec. 2022 (€480.10 Mil) to Dec. 2023 (€473.11 Mil).

Aspira Womens Health Additional Paid-In Capital Historical Data

The historical data trend for Aspira Womens Health's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Additional Paid-In Capital Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

387.72

369.64

444.18

480.10

473.11

Aspira Womens Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															472.40	467.73	482.13	473.11	479.83

Aspira Womens Health Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Aspira Womens Health Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Additional Paid-In Capital

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines